|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sordella R, Bell DW, Haber DA and
Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer
activate anti-apoptotic pathways. Science. 305:1163–1167. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Workman P: Altered states: Selectively
drugging the Hsp90 cancer chaperone. Trends Mol Med. 10:47–51.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kobayashi N, Toyooka S, Soh J, Yamamoto H,
Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, et al: The
anti-proliferative effect of heat shock protein 90 inhibitor,
17-DMAG, on non-small-cell lung cancers being resistant to EGFR
tyrosine kinase inhibitor. Lung cancer. 75:161–166. 2012.
View Article : Google Scholar
|
|
5
|
Langer CJ: Epidermal growth factor
receptor inhibition in mutation-positive non-small-cell lung
cancer: Is afatinib better or simply newer? J Clin Oncol.
31:3303–3306. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arcila ME, Nafa K, Chaft JE, Rekhtman N,
Lau C, Reva BA, Zakowski MF, Kris MG and Ladanyi M: EGFR exon 20
insertion mutations in lung adenocarcinomas: Prevalence, molecular
heterogeneity, and clinicopathologic characteristics. Mol Cancer
Ther. 12:220–229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adeno-carcinomas to gefitinib or erlotinib is associated with
a second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar
|
|
8
|
Gainor JF and Shaw AT: Emerging paradigms
in the development of resistance to tyrosine kinase inhibitors in
lung cancer. J Clin Oncol. 31:3987–3996. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lutz ST, Jones J and Chow E: Role of
radiation therapy in palliative care of the patient with cancer. J
Clin Oncol. 32:2913–2919. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Socinski MA, Rosenman JG, Halle J, Schell
MJ, Lin Y, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, et
al: Dose-escalating conformal thoracic radiation therapy with
induction and concurrent carboplatin/paclitaxel in unresectable
stage IIA/B nonsmall cell lung carcinoma: A modified phase I/II
trial. Cancer. 92:1213–1223. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Santana-Davila R, Devisetty K, Szabo A,
Sparapani R, Arce-Lara C, Gore EM, Moran A, Williams CD, Kelley MJ
and Whittle J: Cisplatin and etoposide versus carboplatin and
paclitaxel with concurrent radiotherapy for stage III
non-small-cell lung cancer: an analysis of Veterans Health
Administration data. J Clin Oncol. 33:567–574. 2015. View Article : Google Scholar :
|
|
13
|
Jiang H, Zhao P, Feng J, Su D and Ma S:
Effect of Paris saponin I on radiosensitivity in a
gefitinib-resistant lung adenocarcinoma cell line. Oncol Lett.
7:2059–2064. 2014.PubMed/NCBI
|
|
14
|
Yan L, Gao W, Zhang Y and Wang Y: A new
phenylpropanoid glycosides from Paris polyphylla var. yunnanensis.
Fitoterapia. 79:306–307. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Negi JS, Bisht VK, Bhandari AK, Bhatt VP,
Singh P and Singh N: Paris polyphylla: Chemical and biological
prospectives. Anticancer Agents Med Chem. 14:833–839. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He H, Zheng L, Sun YP, Zhang GW and Yue
ZG: Steroidal saponins from Paris polyphylla suppress adhesion,
migration and invasion of human lung cancer A549 cells via
down-regulating MMP-2 and MMP-9. Asian Pac J Cancer Prev.
15:10911–10916. 2014. View Article : Google Scholar
|
|
17
|
Cheng ZX, Liu BR, Qian XP, Ding YT, Hu WJ,
Sun J and Yu LX: Proteomic analysis of anti-tumor effects by
Rhizoma Paridis total saponin treatment in HepG2 cells. J
Ethnopharmacol. 120:129–137. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Man S, Gao W, Zhang Y, Yan L, Ma C, Liu C
and Huang L: Anti-tumor and antimetastatic activities of Rhizoma
Paridis saponins. Steroids. 74:1051–1056. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma DD, Lu HX, Xu LS and Xiao W:
Polyphyllin D exerts potent anti-tumour effects on Lewis cancer
cells under hypoxic conditions. J Int Med Res. 37:631–640. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shuli M, Wenyuan G, Yanjun Z, Chaoyi M,
Liu Y and Yiwen L: Paridis saponins inhibiting carcinoma growth and
metastasis in vitro and in vivo. Arch Pharm Res. 34:43–50. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
GuangLie C, WeiShi G, GaiLing H and
JianPing C: Effect of Paris saponin on antitumor and immune
function in U14 tumor-bearing mice. Afr J Tradit Complement Altern
Med. 10:503–507. 2013.PubMed/NCBI
|
|
22
|
Wen F, Yin H, Chen C, Liu X, Xue D, Chen
T, He J and Zhang H: Chemical characteristics of saponins from
Paris fargesii var. brevipetala and cytotoxic activity of its main
ingredient, Paris saponin H. Fitoterapia. 83:627–635. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao Y, Kang LP, Liu YX, Liang YG, Tan DW,
Yu ZY, Cong YW and Ma BP: Steroidal saponins from the rhizome of
Paris poly- phylla and their cytotoxic activities. Planta Med.
75:356–363. 2009. View Article : Google Scholar
|
|
24
|
Yan LL, Zhang YJ, Gao WY, Man SL and Wang
Y: In vitro and in vivo anticancer activity of steroid saponins of
Paris polyphylla var. yunnanensis. Exp Oncol. 31:27–32.
2009.PubMed/NCBI
|
|
25
|
He H, Sun YP, Zheng L and Yue ZG:
Steroidal saponins from Paris polyphylla induce apoptotic cell
death and autophagy in A549 human lung cancer cells. Asian Pac J
Cancer Prev. 16:1169–1173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang H, Zhao PJ, Su D, Feng J and Ma SL:
Paris saponin I induces apoptosis via increasing the Bax/Bcl-2
ratio and caspase-3 expression in gefitinib-resistant non-small
cell lung cancer in vitro and in vivo. Mol Med Rep. 9:2265–2272.
2014.PubMed/NCBI
|
|
27
|
Xiao X, Bai P, Bui Nguyen TM, Xiao J, Liu
S, Yang G, Hu L, Chen X, Zhang X, Liu J and Wang H: The antitumoral
effect of Paris Saponin I associated with the induction of
apoptosis through the mitochondrial pathway. Mol Cancer Ther.
8:1179–1188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xiao M, Dai X, He X, Zhou R, Zhang B, Hu
G, Huang Z and Fan X: Paris saponin I induces G2/M cell
cycle arrest and apoptosis in human gastric carcinoma SGC7901
cells. J Huazhong Univ Sci Technolog Med Sci. 31:768–772. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao P, Jiang H, Su D, Feng J, Ma S and
Zhu X: Inhibition of cell proliferation by mild hyperthermia at
43°C with Paris Saponin I in the lung adenocarcinoma cell line
PC-9. Mol Med Rep. 11:327–332. 2015.
|
|
30
|
Xiao X, Yang M, Xiao J, Zou J, Huang Q,
Yang K, Zhang B, Yang F, Liu S, Wang H and Bai P: Paris Saponin II
suppresses the growth of human ovarian cancer xenografts via
modulating VEGF-mediated angiogenesis and tumor cell migration.
Cancer Chemother Pharmacol. 73:807–818. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xiao X, Zou J, Bui-Nguyen TM, Bai P, Gao
L, Liu J, Liu S, Xiao J, Chen X, Zhang X and Wang H: Paris saponin
II of Rhizoma Paridis - a novel inducer of apoptosis in human
ovarian cancer cells. Biosci Trends. 6:201–211. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Y, Sun Y, Fan L, Zhang F, Meng J, Han
J, Guo X, Zhang D, Zhang R, Yue Z and Mei Q: Paris saponin VII
inhibits growth of colorectal cancer cells through Ras signaling
pathway. Biochem Pharmacol. 88:150–157. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang W, Zhang D, Ma X, Liu Z, Li F and Wu
D: Paris saponin VII suppressed the growth of human cervical cancer
Hela cells. Eur J Med Res. 19:412014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fan L, Li Y, Sun Y, Yue Z, Meng J, Zhang
X, Zhang R, Zhang D, Zhang F and Mei Q: Paris saponin VII inhibits
metastasis by modulating matrix metalloproteinases in colorectal
cancer cells. Mol Med Rep. 11:705–711. 2015.
|
|
35
|
Li Y, Fan L, Sun Y, Miao X, Zhang F, Meng
J, Han J, Zhang D, Zhang R, Yue Z and Mei Q: Paris saponin VII from
trillium tschonoskii reverses multidrug resistance of
adriamycin-resistant MCF-7/ADR cells via P-glycoprotein inhibition
and apoptosis augmentation. J Ethnopharmacol. 154:728–734. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ji Y, Ma SL, Zhang YP, Tang JJ, Wu YM and
Lu YJ: Combined treatment with TNF-α/gefitinib alleviates the
resistance to gefitinib in PC-9 cells. Anticancer Drugs.
20:832–837. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Deckbar D, Jeggo PA and Löbrich M:
Understanding the limitations of radiation-induced cell cycle
checkpoints. Crit Rev Biochem Mol Biol. 46:271–283. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
McIlwain DR, Berger T and Mak TW: Caspase
functions in cell death and disease. Cold Spring Harb Perspect
Biol. 5:a0086562013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hu Q, Peng J, Liu W, He X, Cui L, Chen X,
Yang M, Liu H, Liu S and Wang H: Elevated cleaved caspase-3 is
associated with shortened overall survival in several cancer types.
Int J Clin Exp Pathol. 7:5057–5070. 2014.PubMed/NCBI
|
|
40
|
Dhar R, Persaud SD, Mireles JR and Basu A:
Proteolytic cleavage of p70 ribosomal S6 kinase by caspase-3 during
DNA damage-induced apoptosis. Biochemistry. 48:1474–1480. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shroff EH, Snyder C and Chandel NS: Bcl-2
family members regulate anoxia-induced cell death. Antioxid Redox
Signal. 9:1405–1409. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Engelman JA and Jänne PA: Mechanisms of
acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in non-small cell Lung cancer. Clin Cancer Res.
14:2895–2899. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Huang S, Benavente S, Armstrong EA, Li C,
Wheeler DL and Harari PM: p53 modulates acquired resistance to EGFR
inhibitors and radiation. Cancer Res. 71:7071–7079. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Begg AC, Stewart FA and Vens C: Strategies
to improve radiotherapy with targeted drugs. Nat Rev Cancer.
11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chetty C, Bhoopathi P, Rao JS and Lakka
SS: Inhibition of matrix metalloproteinase-2 enhances
radiosensitivity by abrogating radiation-induced FoxM1-mediated
G2/M arrest in A549 lung cancer cells. Int J Cancer. 124:2468–2477.
2009. View Article : Google Scholar : PubMed/NCBI
|
